{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-243702","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2022-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.141536+00:00","generated_at":"2026-06-23T09:56:02.280038+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alnylam prices $900M convertible senior notes at 1.00% due 2027; conversion premium 35%","bullets":["Principal $900M (greenshoe up to $135M); interest 1.00% semi-annual; maturity Sept 15, 2027.","Initial conversion price ~$286.20/share, 35% premium over $212.00 close on Sept 12, 2022.","Net proceeds est. $883.2M (or $1,015.8M with greenshoe); $762M to repay credit facility, $103.1M for capped call.","Capped call cap price $424.00/share, reducing dilution upon conversion; counterparties may hedge in open market.","Offering expected to close Sept 15, 2022, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-243702","json":"https://secwatch.observer/filing/0001193125-22-243702.json","markdown":"https://secwatch.observer/filing/0001193125-22-243702.md","text":"https://secwatch.observer/filing/0001193125-22-243702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522243702/0001193125-22-243702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522243702/d397120d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:56:02.280038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}